Several companies around the world are working on vaccines to prevent corona virus, but very few have entered the human testing phase.
One of the earliest vaccines is being developed in China, and preliminary human test results were released in May that were considered encouraging.
The vaccine is being developed by Chinese company Ken Sino Biologic in collaboration with the Chinese Army's research unit, the Academy of Military Sciences (AMS).
The Ed5NV vaccine is one of eight vaccines in China that are undergoing human testing, and has been approved for human testing in Canada.
The vaccine has also been released in the second phase of a trial on humans, which it says is safe for people and helps provide an immune response to code 19.
The second phase of the vaccine was to test its safety and ability to develop immunity to the virus, and more people were involved than in the first phase.
However, the researchers emphasized that while volunteers have not been infected with the new corona virus after vaccination, it is not yet possible to fully determine whether it can effectively protect against Code 19.
He said that in the second phase also, there is evidence that the vaccine is safe and effective against code 19 as was discovered in the first phase.
He added that this is an important development in the testing of experimental vaccines and that the third phase of trials is still ongoing.
It is estimated that more than 250 corona vaccines are currently being developed worldwide, and 17 of them are undergoing human testing.
The Chinese vaccine used the adenovirus virus, a common cold virus that infects humans, to provide the genetic material to the immune system to provide information about the spike protein of the new corona virus in cells.
These cells will then be able to make spike proteins and travel to the lymph nodes so that the immune system can produce antibodies that recognize the spike protein and fight the corona virus.
The second phase of the vaccine trial involved 508 people, of whom 253 were given high doses of the vaccine, 129 were given low doses and 126 were given a medical substance placebo.
Two-thirds (309) were between the ages of 18 and 44, a quarter (134) were between 45 and 54, and 13 percent (65) were 55 or older.
These volunteers were exposed to any side effects for up to 30 minutes immediately after the injection and then evaluated for 14 to 28 days to see if there were any side effects at the injection site or in the body system.
Blood samples from these volunteers showed antibody reactions shortly before and 14 and 28 days after vaccination.
The researchers found that 95%, or 241 out of 253, in the high-dose group, and 91% in the low-dose group, showed the virus-fighting T cells or antibody immune response 28 days after vaccination.
Vaccine-induced antibody reactions were detected in 59% of high-dose, 47% of low-dose, and antibacterial reactions in 96% of high-dose and 97% of low-dose individuals. went.
In contrast, no antibody response was detected in the placebo group.
The researchers said that more or less high doses of corona virus induced reactions in humans, while the T cells reaction was detected in 90% of the high-dose group and 88% of the low-dose group.
The most common side effects observed during the study period were fever, fatigue, and discomfort at the injection site, but their severity was mild or moderate.
The severity of side effects was significantly higher in the high-dose group than in the low-dose group.
It should be noted that in June, the Chinese military approved the use of the vaccine for its personnel in clinical trials after it proved to be safe and somewhat effective. According to a statement issued by Ken Sino on June 25, The Central Military Commission approved the use of the vaccine for the military for one year.
The company said in a statement that the vaccine is currently limited to military use and will not be widely used until approved by the Logistics Support Department.
However, the company declined to say whether the vaccine would be mandatory for Chinese troops or at their discretion.
In April, Chinese medical officials expressed hope that the vaccine, which protects against code 19, would be available for emergency use by September and for the general public early next year.
Gao Fu, head of China's Center for Disease Control and Prevention, told China Global Television Network that clinical trials of the vaccine in the country are currently in the second or third phase and that they may be in the second wave of the epidemic. May be available up to
"We are at the forefront of vaccine development and it is likely that a vaccine will be ready for emergency use by September. These new vaccines could be used for certain groups of people, such as medical workers," Gao Fu said. ۔
